System-Specific Biopharmaceuticals

GlaxoSmithKline plc

GSK repurchases stocks and cooperates to develop new pricing mechanism

GSK's Blenrep Approved by FDA for Multiple Myeloma Treatment

GSK: Belantamab Mafodotin Shows Persistent Benefit in Relapsed/Refractory Multiple Myeloma

ABB Implements Energy-saving Renovation for GSK's Singapore Facility

Jefferies Analyst Maintains Buy Rating on GSK

GSK Enters Strategic Collaboration with LTZ for Cancer Therapies

GSK acquires 9.17 million shares under its share repurchase program

GSK Executives Acquire ADSs Through Dividend Reinvestment

GSK repurchased 8,663,000 shares

WRN Inhibitor Market Entering Growth Phase

GSK Buys Back 8,329,000 Shares Under Repurchase Program

GSK to Present 21 Abstracts on Liver Disease Treatments at 2025 AASLD Meeting

JPMorgan Analyst Reiterates Sell Rating on GSK

Papadakis and Barclays Maintain Hold Rating on GSK

Leuchten and TR | OpenAI – 4o Reiterate Buy Rating on GlaxoSmithKline

GSK Executives Sell Shares

Deutsche Bank Maintains Hold Rating on GlaxoSmithKline

GSK turns profitable in Q3 with revenue growth

GSK Receives EU Orphan Drug Designation for Lung Cancer Treatment

GSK Secures Global Exclusive Rights to COPD Candidate Drug

On December 4, 2025, GSK plc bought 11,764,733 shares in its buyback program, raising total treasury shares to 237,229,577, which is 5.82% of voting rights.1GSK, with Merck, makes hepatitis B vaccines. Recent CDC ACIP talks on vaccination schedules could impact GSK's vaccine supply and distribution.2

TradingView

Key facts: GSK Buyback Reaches 237M Shares; CDC Talks Impact Vaccines

On December 3, 2025, GSK plc acquired 11,546,733 shares in its buyback program, raising total treasury shares to 237,011,577, or 5.81% of voting rights.1GSK executives are set to collaborate with the British government in developing a new pricing regime to replace the criticized VPAG scheme.2

Key facts: GSK Buyback Reaches 237M Shares; New Pricing Regime Planned

The UK Government secured a 0% US import tariff on pharmaceuticals, benefiting UK pharma companies like GSK and AstraZeneca. The deal includes capping VPAG payback at 15% for 2026-28 and increasing NICE's cost-effectiveness threshold by 25%. The government will double GDP allocation to innovative drugs over ten years. These changes aim to improve the UK pharma sector's competitiveness and support NHS medicine provision.

Pharmaceutical Technology

Win for pharma in UK – zero US tariffs, VPAG rate cap and NICE threshold increase

UK Government to Consult Executives from AstraZeneca, GSK on New Drug Pricing Regime

marketscreener

Astrazeneca

AstraZeneca PLC

UK Government to Consult Executives from AstraZeneca, GSK on New Drug Pricing Regime

On December 2, 2025, GSK plc acquired 11,346,733 shares in its buyback program, increasing treasury shares to 236,811,577, or 5.81% of total voting rights.1GSK produces the hepatitis B vaccine, recommended for American children in three doses. A U.S. committee will vote on delaying these shots, potentially affecting vaccine supply chains.2

Key facts: GSK buyback boosts treasury shares; U.S. committee to vote on vaccine delay

Health care stocks declined Tuesday afternoon, with NYSE Health Care Index down 0.5%. Richard Pazdur plans to retire from FDA weeks after appointment. CVS Health agreed to pay $37.8M to settle allegations of over-dispensing insulin pens. Bristol-Myers Squibb's bid to dismiss a $6.7B lawsuit was rejected. AstraZeneca and GSK invited to join UK drug-pricing panel. CVS shares fell 2.1%, Bristol-Myers 1.5%, AstraZeneca 0.3%, GSK rose 1.9%.

fidelity

CVS Health

Bristol Myers Squibb

Sector Update: Health Care Stocks Lower Tuesday Afternoon

AstraZeneca, GSK to Join UK Working Group on New Drug-Pricing Framework

AstraZeneca, GSK to Join UK Working Group on New Drug-Pricing Framework

MREO

European equities traded in the US as American Depositary Receipts rose 0.58% on the S&P Europe Select ADR Index. Notable gainers included Sequans Communications and Materialise, while Unilever and Novo Nordisk led the decliners. From the UK and Ireland, GSK and Vodafone Group were among the top gainers, whereas Silence Therapeutics and Mereo BioPharma Group were the main decliners.

Mereo Biopharma

Silence Therapeutics

Novo Nordisk AS

Vodafone 

European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading

GSK.WI

GSK PLC announced the purchase of 203,000 of its own ordinary shares at prices ranging from 1,786.00p to 1,810.00p, with a volume-weighted average price of 1,800.44p. These shares will be held as treasury shares, part of the company's ongoing buyback program. Following this purchase, GSK holds 236,811,577 shares in treasury, with 4,078,622,107 shares in issue. The transaction was conducted through BNP Paribas SA.

London Stock Exchange

GSK plc Sponsored ADR

REG - GSK PLC - Transaction in Own Shares

GSK shares increased by approximately 1.4% to 1,815.5 pence, following positive market sentiment regarding a potential zero-tariff deal for pharmaceutical products between the UK and the U.S.1GSK presented data at the American Society of Hematology (ASH) conference, showcasing advancements that could redefine treatment outcomes for patients with blood cancers.2On December 1, 2025, GSK reported 4.08 billion voting rights and bought back 11.14 million shares, raising treasury shares to 236.61 million, or 5.80% of total voting rights.3

Key facts: GSK shares rise 1.4%; presents blood cancer data at ASH; buyback increases treasury shares

Shares in UK-based pharmaceutical firms rise as Britain and the U.S. are close to agreeing on zero tariffs for pharmaceutical products, according to sourcesShares in GSK (GSK.L) up near 1.4% at 1,815.5 p, Hikma(HIK.L) up 1.15% at 1,572p while AstraZeneca (AZN.L) marginally up 0.5% at 14,044pAnnouncement expected from White HouseThe White House and the British government did not immediately respond to Reuters requests for comment

Reuters

BUZZ-UK pharma stocks gain on prospects of UK-US zero-tariff deal

GSK PLC announced transactions involving its directors and PDMRs, including James Ford, David Redfern, and Victoria Whyte. Each was granted options over Ordinary Shares under the Share Save Plan 2022, priced at £14.19643 per share, conducted on November 28, 2025, at the London Stock Exchange. This is an initial notification of these transactions.

REG - GSK PLC - Director/PDMR Shareholding

GSK plc has received FDA approval in the US for its drug Blenrep, in combination with bortezomib and dexamethasone, for treating relapsed or refractory multiple myeloma in adults. The drug is also under review in other global markets, including China, and is approved in the EU, UK, Japan, Canada, Switzerland, and Brazil.

GSK Wins FDA Approval for Blenrep Combo in Relapsed Multiple Myeloma

GSK: Long-term data from DREAMM-7, DREAMM-8 highlight sustained benefits of belantamab mafodotin in treatment of relapsed/refractory multiple myeloma